Q

Quazepam

Ability to drive, quazepam

The sedative effect affects the ability to drive or use machines

Alcohol, quazepam

The co-administration may cause a mutual potentiation of the depressor effect on the CNS. Alcohol consumption should be avoided

Anaesthetics, quazepam

The co-administration may cause a mutual potentiation of the depressor effect on the CNS

Antidepressants, quazepam

The co-administration may cause a mutual potentiation of the depressor effect on the CNS

Antiepileptics, quazepam

The co-administration may cause a mutual potentiation of the depressor effect on the CNS

Anxiolytics, quazepam

The co-administration may cause a mutual potentiation of the depressor effect on the CNS

Breast-feeding, quazepam

Benzodiazepine passes into the breast milk. Contraindicated

CNS depressants, quazepam

The co-administration may cause a mutual potentiation of the depressor effect on the CNS

Enzyme inhibitors, quazepam

Known inhibitors of hepatic enzymes, particularly cytochrome P450 have been shown to reduce the clearance of benzodiazepines and may potentiate their action

Hypnotics, quazepam

The co-administration may cause a mutual potentiation of the depressor effect on the CNS

Neuroleptics, quazepam

The co-administration may enhance the depressive effect on the central nervous system (e.g. increased sedation, respiratory depression)

Opioid analgesics, quazepam

The co-administration may cause a mutual potentiation of the depressor effect on the CNS, enhance the euphoric effect and promote a psychic dependency

Pregnancy, quazepam

The benzodiazepine crosses the placental barrier. Contraindicated

Quazepam, sedating antihistamines

The co-administration may cause a mutual potentiation of the depressor effect on the CNS

Quazepam, sedatives

The co-administration may cause a mutual potentiation of the depressor effect on the CNS

Quazepam, tetracyclic antidepressant

The co-administration may cause a mutual potentiation of the depressor effect on the CNS

Quazepam, tricyclic antidepressant

The co-administration may cause a mutual potentiation of the depressor effect on the CNS

Quetiapine

Ability to drive, quetiapine [2] ---> SmPC of [2] of eMC

Given its primary central nervous system effects, quetiapine may interfere with activities requiring mental alertness.

Alcohol, quetiapine [2] ---> SmPC of [2] of eMC

Given the primary central nervous system effects, quetiapine should be used with caution in combination with alcohol.

Atazanavir [1], quetiapine ---> SmPC of [1] of EMA

Due to CYP3A4 inhibition by REYATAZ, concentrations of quetiapine are expected to increase. Co-administration of quetiapine with REYATAZ is contraindicated as REYATAZ may increase quetiapine-related toxicity.

Atazanavir [1], quetiapine ---> SmPC of [1] of EMA

Atazanavir is metabolised in the liver through CYP3A4. It inhibits CYP3A4. Therefore, REYATAZ is contraindicated with medicinal products that are substrates of CYP3A4 and have a narrow therapeutic index

Atazanavir/cobicistat [1], quetiapine ---> SmPC of [1] of EMA

Co-administration of medicinal products that are substrates of CYP3A and have narrow therapeutic indexes and for which elevated plasma concentrations are associated with serious and/or life-threatening events are contraindicated with EVOTAZ.

Azole antifungals, quetiapine [2] ---> SmPC of [2] of eMC

The strong CYP3A4 inhibition may increase the plasma concentrations of quetiapine. Concomitant use of quetiapine with CYP3A4 inhibitors is contraindicated.

Boceprevir [1], quetiapine ---> SmPC of [1] of EMA

Concomitant administration of Victrelis and quetiapine may increase plasma concentrations of quetiapine leading to quetiapine-related toxicity, including coma. Coadministration of quetiapine with Victrelis is contraindicated

Boceprevir/peginterferon alfa/ribavirin [1], quetiapine ---> SmPC of [1] of EMA

Victrelis, with peginterferon alfa and ribavirin, is contraindicated in coadministration with medicines that are highly dependent on CYP3A4/5 for clearance, and for which elevated plasma levels are associated with serious and/or life-threatening events

Breast-feeding, quetiapine [2] ---> SmPC of [2] of eMC

Women who are breast-feeding should be advised to avoid breast-feeding while taking quetiapine.

Carbamazepine [1], quetiapine ---> SmPC of [1] of eMC

The active metabolite carbamazepine-10,11-epoxide plasma levels may be increased. Carbamazepine may lower the plasma level of quetiapine

Cimetidine, quetiapine [2] ---> SmPC of [2] of eMC

The pharmacokinetics of quetiapine was not altered following co-administration with cimetidine.

Clarithromycin, quetiapine [2] ---> SmPC of [2] of eMC

The strong CYP3A4 inhibition may increase the plasma concentrations of quetiapine. Concomitant use of quetiapine with CYP3A4 inhibitors is contraindicated.

CNS depressants, quetiapine [2] ---> SmPC of [2] of eMC

Given the primary central nervous system effects, quetiapine should be used with caution in combination with other centrally acting medicinal products and alcohol.

CYP3A4 inhibitors, quetiapine [2] ---> SmPC of [2] of eMC

The CYP3A4 inhibition may increase the plasma concentrations quetiapine. Concomitant use of quetiapine with CYP3A4 inhibitors is contraindicated.

Darunavir/cobicistat [1], quetiapine ---> SmPC of [1] of EMA

Co-administration of darunavir/cobicistat with active substances that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide [1], quetiapine ---> SmPC of [1] of EMA

Co-administration is contraindicated due to the potential for serious and/or life-threatening adverse reactions

Darunavir/ritonavir, quetiapine ---> SmPC of [darunavir] of EMA

Co-administration of darunavir boosted with ritonavir, with active substances that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious and/or life-threatening events is contraindicated

Dasabuvir with ombitasvir/paritaprevir/ritonavir, quetiapine ---> SmPC of [ombitasvir/paritaprevir/ritonavir] of E

Ritonavir is a strong inhibitor of CYP3A. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events are contraindicated

Electrolyte imbalance, quetiapine [2] ---> SmPC of [2] of eMC

Caution should be exercised when quetiapine is used concomitantly with medicinal products known to cause electrolyte imbalance

Enzyme inductors, quetiapine [2] ---> SmPC of [2] of eMC

In patients receiving a hepatic enzyme inducer, initiation of quetiapine treatment should only occur if the physician considers that the benefits of quetiapine outweigh the risks of removing the hepatic enzyme inducer

Erythromycin, quetiapine [2] ---> SmPC of [2] of eMC

The strong CYP3A4 inhibition may increase the plasma concentrations of quetiapine. Concomitant use of quetiapine with CYP3A4 inhibitors is contraindicated.

Fluoxetine, quetiapine [2] ---> SmPC of [2] of eMC

The pharmacokinetics of quetiapine were not significantly altered by co-administration of the antidepressants imipramine (a known CYP 2D6 inhibitor) or fluoxetine (a known CYP 3A4 and CYP 2D6 inhibitor)

Fluvoxamine [1], quetiapine ---> SmPC of [1] of eMC

An increase in previously stable plasma levels of medicinal products which are largely metabolised through cytochrome P450 1A2 when given together with fluvoxamine, has been reported. (N.B.: I think that quetiapine is mainly metabolized by CYP3A4)

Fosamprenavir/ritonavir, quetiapine ---> SmPC of [fosamprenavir] of EMA

The CYP3A inhibition by amprenavir can increase the concentrations of quetiapine (which may lead to coma). Concomitant administration of amprenavir and quetiapine is contraindicated as it may increase quetiapine-related toxicity.

Grapefruit juice, quetiapine [2] ---> SmPC of [2] of eMC

The strong CYP3A4 inhibition may increase the plasma concentrations of quetiapine. The intake of grapefruit/grapefruit juice should be avoided

Haloperidol, quetiapine [2] ---> SmPC of [2] of eMC

The pharmacokinetics of quetiapine were not significantly altered by co-administration of the antipsychotics risperidone or haloperidol.

Idelalisib [1], quetiapine ---> SmPC of [1] of EMA

The co-administration of idelalisib with quetiapine may increase the serum concentrations of quetiapine. Idelalisib should not be co-administered with quetiapine.

Imipramine, quetiapine [2] ---> SmPC of [2] of eMC

The pharmacokinetics of quetiapine were not significantly altered by co-administration of the antidepressants imipramine (a known CYP 2D6 inhibitor) or fluoxetine (a known CYP 3A4 and CYP 2D6 inhibitor)

Indinavir [1], quetiapine ---> SmPC of [1] of EMA

Concomitant administration of indinavir and quetiapine may increase plasma concentrations of quetiapine leading to quetiapine-related toxicity, including coma. Co-administration of quetiapine with indinavir is contraindicated

Indinavir/ritonavir, quetiapine ---> SmPC of [indinavir] of EMA

Concomitant administration of indinavir and quetiapine may increase plasma concentrations of quetiapine leading to quetiapine-related toxicity, including coma. Co-administration of quetiapine with indinavir is contraindicated

Ketoconazole [1], quetiapine ---> SmPC of [1] of EMA

Contraindicated as it may increase quetiapine-related toxicity

Lithium, quetiapine [2] ---> SmPC of [2] of eMC

The pharmacokinetics of lithium was not altered when co-administered with quetiapine.

Lopinavir/ritonavir [1], quetiapine ---> SmPC of [1] of EMA

Due to CYP3A inhibition by lopinavir/ritonavir, concentrations of quetiapine are expected to increase. Concomitant administration of lopinavir/ritonavir and quetiapine is contraindicated as it may increase quetiapine-related toxicity

Moderate CYP3A4 inhibitors, quetiapine [2] ---> SmPC of [2] of eMC

The moderate CYP3A4 inhibition may increase the plasma concentrations quetiapine. Concomitant use of quetiapine with CYP3A4 inhibitors is contraindicated.

Nefazodone, quetiapine [2] ---> SmPC of [2] of eMC

The strong CYP3A4 inhibition may increase the plasma concentrations of quetiapine. Concomitant use of quetiapine with CYP3A4 inhibitors is contraindicated.

Niraparib [1], quetiapine ---> SmPC of [1] of EMA

Caution is recommended when niraparib is combined with principles the metabolism of which is CYP3A4-dependent and, notably, those having a narrow therapeutic range (e.g. ciclosporin, tacrolimus, alfentanil, ergotamine, pimozide, quetiapine, and halofantrine

Olaparib [1], quetiapine ---> SmPC of [1] of EMA

Olaparib inhibits CYP3A4 in vitro and is predicted to be a mild CYP3A inhibitor in vivo. Therefore, caution should be exercised when sensitive CYP3A substrates or substrates with a narrow therapeutic margin are combined with olaparib.

Ombitasvir/paritaprevir/ritonavir [1], quetiapine ---> SmPC of [1] of EMA

Ritonavir is a strong inhibitor of CYP3A. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events are contraindicated

Phenytoin, quetiapine [2] ---> SmPC of [2] of eMC

Co-administration of quetiapine and phenytoin (a microsomal enzyme inducer) caused a greatly increased clearance of quetiapine by approximately 450%

Pregnancy, quetiapine [2] ---> SmPC of [2] of eMC

Quetiapine should only be used during pregnancy if the benefits justify the potential risks.

Protease inhibitors, quetiapine [2] ---> SmPC of [2] of eMC

The strong CYP3A4 inhibition may increase the plasma concentrations of quetiapine. Concomitant use of quetiapine with CYP3A4 inhibitors is contraindicated.

QT interval prolonging drugs, quetiapine [2] ---> SmPC of [2] of eMC

Caution should be exercised when quetiapine is used concomitantly with medicinal products known to increase QT-interval.

Quetiapine [1], rifampicin ---> SmPC of [1] of eMC

Rifampicin, enzymatic inductor, may increase the metabolism of quetiapine and decrease its plasma levels and effect

Quetiapine [1], risperidone ---> SmPC of [1] of eMC

The pharmacokinetics of quetiapine were not significantly altered by co-administration of the antipsychotics risperidone or haloperidol.

Quetiapine [1], strong CYP3A4 inhibitors ---> SmPC of [1] of eMC

The strong CYP3A4 inhibition may increase the plasma concentrations of quetiapine. Concomitant use of quetiapine with CYP3A4 inhibitors is contraindicated.

Quetiapine [1], thioridazine ---> SmPC of [1] of eMC

Concomitant use of quetiapine and thioridazine caused an increased clearance of quetiapine with approx. 70%

Quetiapine, ribociclib [2] ---> SmPC of [2] of EMA

Concomitant administration of ribociclib at the 600 mg dose this CYP3A4 substrates should be avoided

Quetiapine, ritonavir [2] ---> SmPC of [2] of EMA

Due to CYP3A inhibition by ritonavir, concentrations of quetiapine are expected to increase. Concomitant administration of Norvir and quetiapine is contraindicated as it may increase quetiapine-related toxicity.

Quetiapine, saquinavir/ritonavir ---> SmPC of [saquinavir] of EMA

Concomitant administration of Invirase and quetiapine is contraindicated as it may increase quetiapine-related toxicity. Increased plasma concentrations of quetiapine may lead to coma

Quetiapine, sodium valproate [2] ---> SmPC of [2] of eMC

The pharmacokinetics of sodium valproate and quetiapine were not altered to a clinically relevant extent when co-administered. A retrospective study of children and adolescents found a higher incidence of leucopenia and neutropenia

Quetiapine, telaprevir [2] ---> SmPC of [2] of EMA

Concomitant administration of telaprevir is contraindicated with active substances that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events.

Quetiapine, tipranavir/ritonavir ---> SmPC of [tipranavir] of EMA

Co-administration of tipranavir with low dose ritonavir, with active substances that are highly dependent on CYP3A for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events, is contraindicated.

           CONTRAINDICATIONS of Quetiapine

           - Hypersensitivity to the active substance or to any of the excipients

           - Concomitant administration of cytochrome P450 3A4 inhibitors, such as HIV-protease inhibitors, azole-antifungal agents, erythromycin, clarithromycin and nefazodone, is contraindicated

           http://www.medicines.org.uk/emc/

Quinagolide

Ability to drive, quinagolide [2] ---> SmPC of [2] of eMC

Since, especially during the first days of treatment, hypotensive reactions may occasionally occur and result in reduced alertness, patients should be cautious when driving a vehicle or operating machinery.

Alcohol, quinagolide [2] ---> SmPC of [2] of eMC

The tolerability of quinagolide may be reduced by alcohol.

Breast-feeding, quinagolide [2] ---> SmPC of [2] of eMC

Breast-feeding cannot be recommended because it is not known whether quinagolide passes into human breast milk.

Chlorpromazine [1], quinagolide ---> SmPC of [1] of eMC

Reciprocal antagonism of dopaminergic agent and neuroleptic. Association contraindicated except with dopaminergic antiparkinsonian agents

Dopamine antagonists, quinagolide [2] ---> SmPC of [2] of eMC

On theoretical grounds, a reduction of the prolactin-lowering effect could be expected when drugs with strong dopamine antagonistic properties are used concomitantly.

Enzyme inhibitors, quinagolide

Caution is recommended when combining quinagolide with other medicinal products, especially with strong inhibitors of enzyme metabolism

Neuroleptics, quinagolide [2] ---> SmPC of [2] of eMC

On theoretical grounds, a reduction of the prolactin-lowering effect could be expected when drugs with strong dopamine antagonistic properties are used concomitantly.

Pregnancy, quinagolide [2] ---> SmPC of [2] of eMC

In patients wishing to conceive, quinagolide should be discontinued when pregnancy is confirmed, unless there is a medical reason for continuing therapy.

Quinagolide [1], serotonin agonists ---> SmPC of [1] of eMC

As the potency of quinagolide for 5-HT 1 and 5-HT 2 receptors is some 100 times lower than that for D2 receptors, an interaction between quinagolide and 5-HT 1a receptors is unlikely.

Quinagolide, tiapride

The combination of dopaminergic agonists, except in case of Parkinson disease, and tiapride is contraindicated due to mutual antagonism between dopaminergic agonists and neuroleptics

           CONTRAINDICATIONS of Quinagolide

           - Hypersensitivity to the drug

           - Impaired hepatic or renal function

           - For procedure during pregnancy, (see 'Section 4.6 Pregnancy and lactation).

           http://www.medicines.org.uk/emc/

Quinapril

Ability to drive, quinapril [2] ---> SmPC of [2] of eMC

When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.

ACE inhibitors, mTOR inhibitors ---> SmPC of [quinapril] of eMC

Concomitant use of ACE inhibitors with mTOR inhibitor therapy may lead to an increased risk for angioedema

AIIRA, quinapril

Dual blockade with ACE inhibitor, angiotensin-receptor blockers or aliskiren is associated with a higher frequency of hypotension, hyperkalaemia, and worsening renal function (including acute renal failure).

Alcohol, quinapril [2] ---> SmPC of [2] of eMC

Potentiation of orthostatic hypotension may occur.

Aliskiren, quinapril

The concomitant use of ARBs with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m²) and is not recommended in other patients

Allopurinol, quinapril [2] ---> SmPC of [2] of eMC

Concomitant administration of allopurinol with ACE inhibitors may lead to an increased risk for leucopenia.

Amiloride, quinapril [2] ---> SmPC of [2] of eMC

Concomitant treatments of quinapril with potassium sparing diuretics, potassium supplements or potassium salts should be used with caution and with appropriate monitoring of serum potassium.

Anaesthetics, quinapril [2] ---> SmPC of [2] of eMC

Angiotensin converting enzyme inhibitors have been shown to block angiotensin II formation secondary to compensatory renin release. This may lead to hypotension

Antacids, quinapril [2] ---> SmPC of [2] of eMC

Antacids may decrease the bioavailability of quinapril

Antihypertensives, quinapril [2] ---> SmPC of [2] of eMC

There may be an additive effect or potentiation.

Aurothiomalate, quinapril [2] ---> SmPC of [2] of eMC

Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (e.g. sodium aurothiomalate) and concomitant ACE inhibitor therapy

Barbiturates, quinapril [2] ---> SmPC of [2] of eMC

Barbiturates may potentiate orthostatic hypotension

Breast-feeding, quinapril [2] ---> SmPC of [2] of eMC

The use of quinapril in breastfeeding is not recommended for preterm infants and for the first few weeks after delivery, because of the hypothetical risk of cardiovascular and renal effects

Cilazapril, temsirolimus ---> SmPC of [quinapril] of eMC

Concomitant use of ACE inhibitors with mTOR inhibitor therapy may lead to an increased risk for angioedema

Corticosteroids, quinapril [2] ---> SmPC of [2] of eMC

Concomitant administration of systemic corticosteroids with ACE inhibitors may lead to an increased risk for leucopenia.

Coxibs, quinapril [2] ---> SmPC of [2] of eMC

The antihypertensive effect of ACE inhibitors may be attenuated by NSAIDs. Co-administration of NSAIDs with ACE inhibitors may result in deterioration of renal function, including possible acute renal failure.

Cytostatics, quinapril [2] ---> SmPC of [2] of eMC

Concomitant administration of cytostatics with ACE inhibitors may lead to an increased risk for leucopenia.

Dextran sulphate, quinapril

Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption.

Dihydropyrimidine dehydrogenase inhibitors 4, quinapril

The co-administration of ACE inhibitors and dipeptidyl peptidase-4 inhibitors may increase the risk of angioedema

Diuretics, quinapril [2] ---> SmPC of [2] of eMC

Patients treated with diuretics may occasionally experience an excessive reduction of blood pressure after initiation of therapy with quinapril

Gold, quinapril [2] ---> SmPC of [2] of eMC

Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (e.g. sodium aurothiomalate) and concomitant ACE inhibitor therapy

Hyperkalemia, quinapril [2] ---> SmPC of [2] of eMC

Concomitant treatments of quinapril with potassium sparing diuretics, potassium supplements or potassium salts should be used with caution and with appropriate monitoring of serum potassium.

Immunosuppressives, quinapril [2] ---> SmPC of [2] of eMC

Concomitant administration of immunosuppressive agents with ACE inhibitors may lead to an increased risk for leucopenia.

Insulin, quinapril [2] ---> SmPC of [2] of eMC

Concomitant treatment with ACE inhibitors and antidiabetic agents may cause a pronounced hypoglycaemic effect with the risk of hypoglycaemia.

Lithium, quinapril [2] ---> SmPC of [2] of eMC

Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy due to the sodium-losing effect of these agents.

MTOR inhibitors, quinapril

The co-administration of ACE inhibitors and mTOR inhibitors may increase the risk of angioedema

Narcotics, quinapril [2] ---> SmPC of [2] of eMC

Narcotics may potentiate orthostatic hypotension

NSAID, quinapril [2] ---> SmPC of [2] of eMC

The antihypertensive effect of ACE inhibitors may be attenuated by NSAIDs. Co-administration of NSAIDs with ACE inhibitors may result in deterioration of renal function, including possible acute renal failure.

Oral antidiabetics, quinapril [2] ---> SmPC of [2] of eMC

Concomitant treatment with ACE inhibitors and antidiabetic agents may cause a pronounced hypoglycaemic effect with the risk of hypoglycaemia.

Potassium-sparing diuretics, quinapril [2] ---> SmPC of [2] of eMC

Concomitant treatments of quinapril with potassium sparing diuretics, potassium supplements or potassium salts should be used with caution and with appropriate monitoring of serum potassium.

Pregnancy, quinapril [2] ---> SmPC of [2] of eMC

The use of ACE inhibitors is not recommended during the first trimester of pregnancy. The use of ACE inhibitors is contraindicated during the 2nd and 3rd trimester of pregnancy

Procainamide, quinapril [2] ---> SmPC of [2] of eMC

Concomitant administration of procainamide with ACE inhibitors may lead to an increased risk for leucopenia.

Quinapril [1], triamterene ---> SmPC of [1] of eMC

Concomitant treatments of quinapril with potassium sparing diuretics, potassium supplements or potassium salts should be used with caution and with appropriate monitoring of serum potassium.

Quinapril, sodium

Decreased hypotensive effect

Quinapril, sympathomimetics

Sympathomimetic may reduce the antihypertensive effects of ACE inhibitor

Quinapril, table salt

Decreased hypotensive effect

Quinapril, temsirolimus

The co-administration of ACE inhibitors and mTOR inhibitors may increase the risk of angioedema

Quinapril, vildagliptin

The co-administration of ACE inhibitors and dipeptidyl peptidase-4 inhibitors may increase the risk of angioedema

           CONTRAINDICATIONS of Quinapril

           - Accupro is contraindicated in patients with hypersensitivity to any of the ingredients.

           - Accupro is contraindicated during the second and third trimesters of pregnancy

           - Accupro is contraindicated in patients with a history of angioedema related to previous treatment with ACE inhibitors.

           - Accupro is contraindicated in patients with hereditary/idiopathic angioneurotic oedema.

           http://www.medicines.org.uk/emc/

Quizartinib (Vanflyta)

Apalutamide, quizartinib [2] ---> SmPC of [2] of EMA

Decreased quizartinib exposure may lead to reduced efficacy. Co-administration of VANFLYTA with strong or moderate CYP3A inducers should be avoided.

Atovaquone, quizartinib [2] ---> SmPC of [2] of EMA

Co-administration of VANFLYTA with other medicinal products that prolong the QT interval may further increase the incidence of QT prolongation. Caution should be used when co-administering medicinal products that prolong the QT interval with VANFLYTA

Azithromycin, quizartinib [2] ---> SmPC of [2] of EMA

Co-administration of VANFLYTA with other medicinal products that prolong the QT interval may further increase the incidence of QT prolongation. Caution should be used when co-administering medicinal products that prolong the QT interval with VANFLYTA

Azole antifungals, quizartinib [2] ---> SmPC of [2] of EMA

Co-administration of VANFLYTA with other medicinal products that prolong the QT interval may further increase the incidence of QT prolongation. Caution should be used when co-administering medicinal products that prolong the QT interval with VANFLYTA

Bosentan, quizartinib [2] ---> SmPC of [2] of EMA

Decreased quizartinib exposure may lead to reduced efficacy. Co-administration of VANFLYTA with strong or moderate CYP3A inducers should be avoided.

Breast-feeding, quizartinib [2] ---> SmPC of [2] of EMA

Because of the potential for serious adverse reactions in breast-fed children, women must not breast-feed during treatment with VANFLYTA and for at least 5 weeks after the last dose (see section 4.3).

Carbamazepine, quizartinib [2] ---> SmPC of [2] of EMA

Decreased quizartinib exposure may lead to reduced efficacy. Co-administration of VANFLYTA with strong or moderate CYP3A inducers should be avoided.

Clarithromycin, quizartinib [2] ---> SmPC of [2] of EMA

Increased quizartinib maximum plasma concentration. Increased quizartinib exposure may increase the risk of toxicity.

Dabigatran etexilate, quizartinib [2] ---> SmPC of [2] of EMA

Quizartinib is a weak P-gp inhibitor, and no dose modification is recommended when P-gp substrates are co-administered with VANFLYTA.

Doxycycline, quizartinib [2] ---> SmPC of [2] of EMA

Co-administration of VANFLYTA with other medicinal products that prolong the QT interval may further increase the incidence of QT prolongation. Caution should be used when co-administering medicinal products that prolong the QT interval with VANFLYTA

Efavirenz, quizartinib [2] ---> SmPC of [2] of EMA

Decreased quizartinib exposure may lead to reduced efficacy. Co-administration of VANFLYTA with strong or moderate CYP3A inducers should be avoided.

Enzalutamide, quizartinib [2] ---> SmPC of [2] of EMA

Decreased quizartinib exposure may lead to reduced efficacy. Co-administration of VANFLYTA with strong or moderate CYP3A inducers should be avoided.

Etravirine, quizartinib [2] ---> SmPC of [2] of EMA

Decreased quizartinib exposure may lead to reduced efficacy. Co-administration of VANFLYTA with strong or moderate CYP3A inducers should be avoided.

Fertility, quizartinib [2] ---> SmPC of [2] of EMA

There are no human data on the effect of quizartinib on fertility. Based on findings in animals, female and male fertility may be impaired during treatment with VANFLYTA (see section 5.3).

Fluconazole [1], quizartinib ---> SmPC of [1] of EMA

Increased quizartinib Cmax and AUCinf by approximately 1.18-fold and 9.7-fold, respectively, compared to VANFLYTA alone. The Cmax and AUCinf of AC886 decreased by approximately 3.1-fold and 26-fold, respectively (see section 5.2).

Gastric pH increasing medication, quizartinib [2] ---> SmPC of [2] of EMA

Proton pump inhibitor lansoprazole decreased quizartinib Cmax by 1.16-fold and AUCinf by 1.05-fold. This decrease in quizartinib absorption was not considered clinically relevant. No dose modification is recommended.

Granisetron, quizartinib [2] ---> SmPC of [2] of EMA

Co-administration of VANFLYTA with other medicinal products that prolong the QT interval may further increase the incidence of QT prolongation. Caution should be used when co-administering medicinal products that prolong the QT interval with VANFLYTA

Itraconazol, quizartinib [2] ---> SmPC of [2] of EMA

Increased quizartinib maximum plasma concentration. Increased quizartinib exposure may increase the risk of toxicity.

Ketoconazole, quizartinib [2] ---> SmPC of [2] of EMA

Increased quizartinib maximum plasma concentration. Increased quizartinib exposure may increase the risk of toxicity.

Lansoprazole, quizartinib [2] ---> SmPC of [2] of EMA

Proton pump inhibitor lansoprazole decreased quizartinib Cmax by 1.16-fold and AUCinf by 1.05-fold. This decrease in quizartinib absorption was not considered clinically relevant. No dose modification is recommended.

Men [1], quizartinib ---> SmPC of [1] of EMA

Male patients with female partners of childbearing potential should use effective contraception during treatment with VANFLYTA and for at least 4 months after the last dose.

Mitotane, quizartinib [2] ---> SmPC of [2] of EMA

Decreased quizartinib exposure may lead to reduced efficacy. Co-administration of VANFLYTA with strong or moderate CYP3A inducers should be avoided.

Moderate CYP3A4 inductors, quizartinib [2] ---> SmPC of [2] of EMA

Decreased quizartinib exposure may lead to reduced efficacy. Co-administration of VANFLYTA with strong or moderate CYP3A inducers should be avoided.

Moxifloxacin, quizartinib [2] ---> SmPC of [2] of EMA

Co-administration of VANFLYTA with other medicinal products that prolong the QT interval may further increase the incidence of QT prolongation. Caution should be used when co-administering medicinal products that prolong the QT interval with VANFLYTA

Nefazodone, quizartinib [2] ---> SmPC of [2] of EMA

Increased quizartinib maximum plasma concentration. Increased quizartinib exposure may increase the risk of toxicity.

Ondansetron, quizartinib [2] ---> SmPC of [2] of EMA

Co-administration of VANFLYTA with other medicinal products that prolong the QT interval may further increase the incidence of QT prolongation. Caution should be used when co-administering medicinal products that prolong the QT interval with VANFLYTA

P-glycoprotein substrates, quizartinib [2] ---> SmPC of [2] of EMA

Quizartinib is a weak P-gp inhibitor, and no dose modification is recommended when P-gp substrates are co-administered with VANFLYTA.

Pentamidine, quizartinib [2] ---> SmPC of [2] of EMA

Co-administration of VANFLYTA with other medicinal products that prolong the QT interval may further increase the incidence of QT prolongation. Caution should be used when co-administering medicinal products that prolong the QT interval with VANFLYTA

Phenobarbital, quizartinib [2] ---> SmPC of [2] of EMA

Decreased quizartinib exposure may lead to reduced efficacy. Co-administration of VANFLYTA with strong or moderate CYP3A inducers should be avoided.

Phenytoin, quizartinib [2] ---> SmPC of [2] of EMA

Decreased quizartinib exposure may lead to reduced efficacy. Co-administration of VANFLYTA with strong or moderate CYP3A inducers should be avoided.

Posaconazole, quizartinib [2] ---> SmPC of [2] of EMA

Increased quizartinib maximum plasma concentration. Increased quizartinib exposure may increase the risk of toxicity.

Pregnancy, quizartinib [2] ---> SmPC of [2] of EMA

VANFLYTA should not be used during pregnancy and in women of childbearing potential not using contraception, unless the clinical condition of the woman requires treatment. Pregnant women should be advised of the potential risk to the foetus.

Primidone, quizartinib [2] ---> SmPC of [2] of EMA

Decreased quizartinib exposure may lead to reduced efficacy. Co-administration of VANFLYTA with strong or moderate CYP3A inducers should be avoided.

Prochlorperazine, quizartinib [2] ---> SmPC of [2] of EMA

Co-administration of VANFLYTA with other medicinal products that prolong the QT interval may further increase the incidence of QT prolongation. Caution should be used when co-administering medicinal products that prolong the QT interval with VANFLYTA

Proton pump inhibitors, quizartinib [2] ---> SmPC of [2] of EMA

Proton pump inhibitor lansoprazole decreased quizartinib Cmax by 1.16-fold and AUCinf by 1.05-fold. This decrease in quizartinib absorption was not considered clinically relevant. No dose modification is recommended.

QT interval prolonging drugs, quizartinib [2] ---> SmPC of [2] of EMA

Co-administration of VANFLYTA with other medicinal products that prolong the QT interval may further increase the incidence of QT prolongation. Caution should be used when co-administering medicinal products that prolong the QT interval with VANFLYTA

Quizartinib [1], rifampicin ---> SmPC of [1] of EMA

Decreased quizartinib exposure may lead to reduced efficacy. Co-administration of VANFLYTA with strong or moderate CYP3A inducers should be avoided.

Quizartinib [1], ritonavir ---> SmPC of [1] of EMA

Increased quizartinib maximum plasma concentration. Increased quizartinib exposure may increase the risk of toxicity.

Quizartinib [1], St. John's wort ---> SmPC of [1] of EMA

Decreased quizartinib exposure may lead to reduced efficacy. Co-administration of VANFLYTA with strong or moderate CYP3A inducers should be avoided.

Quizartinib [1], strong CYP3A4 inductors ---> SmPC of [1] of EMA

Decreased quizartinib exposure may lead to reduced efficacy. Co-administration of VANFLYTA with strong or moderate CYP3A inducers should be avoided.

Quizartinib [1], strong CYP3A4 inhibitors ---> SmPC of [1] of EMA

Increased quizartinib maximum plasma concentration. Increased quizartinib exposure may increase the risk of toxicity.

Quizartinib [1], tacrolimus ---> SmPC of [1] of EMA

Co-administration of VANFLYTA with other medicinal products that prolong the QT interval may further increase the incidence of QT prolongation. Caution should be used when co-administering medicinal products that prolong the QT interval with VANFLYTA

Quizartinib [1], telithromycin ---> SmPC of [1] of EMA

Increased quizartinib maximum plasma concentration. Increased quizartinib exposure may increase the risk of toxicity.

Quizartinib [1], voriconazole ---> SmPC of [1] of EMA

Increased quizartinib maximum plasma concentration. Increased quizartinib exposure may increase the risk of toxicity.

Quizartinib [1], women of childbearing potential ---> SmPC of [1] of EMA

Women of childbearing potential should undergo pregnancy testing within 7 days before starting treatment with VANFLYTA and should use effective contraception during treatment with VANFLYTA and for at least 7 months after the last dose.

             CONTRAINDICATIONS of Quizartinib (Vanflyta)            

             - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

             - Congenital long QT syndrome (see section 4.4).

             - Breast-feeding (see section 4.6).

             https://www.ema.europa.eu/en/documents/product-information/vanflyta-epar-product-information_en.pdf  18/12/2024